P
Primmune Therapeutics
Primmune Therapeutics is a Biotechnology company
About Primmune Therapeutics
Primmune Therapeutics, a clinical-stage biotechnology firm established in 2017, is focused on developing orally administered small molecules to modulate the innate immune system for therapeutic benefit in oncology and virology. The company was co-founded by James Appleman, Ph.D., Paulo Rangel, and Stephen Webber, Ph.D. The leadership team's background is deeply rooted in drug discovery and immunotherapy. Dr. Appleman, the Chief Scientific Officer, previously co-founded eFFECTOR Therapeutics and played a key role at Anadys Pharmaceuticals in the development of ANA773, a novel TLR7 agonist, providing him with direct experience in the company's core area of focus. President and CEO Charles McDermott brings extensive executive experience from life sciences companies like Impact Biomedicines, which was acquired by Celgene, and Kala Pharmaceuticals.
The company's business model is centered on the research and development of proprietary drug candidates, with a strategy of advancing these assets through clinical trials to demonstrate safety and efficacy. Primmune operates as a venture-backed private entity, having secured significant funding to advance its pipeline. The company has raised a total of $51.4M over several rounds, including a Series A financing of $31.4 million, with investors such as CAM Capital, Polaris Partners, Bioqube Ventures, and Samsara BioCapital. Its goal is to partner with larger pharmaceutical companies for late-stage development and commercialization or to be an acquisition target, a path familiar to its executive team.
Primmune's lead product candidate is PRTX007, an orally administered, small molecule agonist of Toll-like receptor 7 (TLR7). TLR7 is a sensor in the innate immune system that detects single-stranded RNA from viruses. PRTX007 is engineered to systemically activate the innate immune response in a controlled manner. A key feature of PRTX007 is its ability to stimulate plasmacytoid dendritic cells (pDCs) to produce a poly-interferon response, which is critical for antiviral and anti-tumor activity, without causing a surge in pro-inflammatory cytokines like IL-6 and TNFα that can lead to dose-limiting toxicities. This 'tuned' immune activation allows for chronic dosing, potentially making it an ideal combination therapy partner for checkpoint inhibitors in cancer treatment, aiming to improve response rates and durability for patients who do not respond to current immunotherapies. In addition to oncology, Primmune is developing PRTX007 as a broad-spectrum antiviral. The company was awarded a contract of over $22 million from the Defense Threat Reduction Agency (DTRA) to develop PRTX007 for Lassa fever and other hemorrhagic viruses.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- San Diego, United States
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 75.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2026 | $8.6M | $34M | Oberland Capital · Samsara BioCapital · Bioqube Ventures | ↗ |
| SERIES AOther financing | Nov 2021 | $8.4M | $34M | Undisclosed | — |
Growth signals
Latest recorded traffic for Primmune Therapeutics is 2.8K monthly website visits, up 330.8% over the last three months. Primmune Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Primmune Therapeutics in the San Diego ecosystem
The Primmune Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
CAM Capital- BVBioRock Ventures
- BIBioBrit
Series A5 investors entered at this stage
Polaris Partners
Oberland Capital
McDermott International
Samsara BioCapital
Bioqube Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Primmune Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Primmune Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









